Supernus Pharmaceuticals to make $33.4 million CVR milestone payment
Supernus Pharmaceuticals (NASDAQ: SUPN) is obligated to make a $33.4 million Contingent Value Rights (CVR) milestone payment to eligible holders after achieving "Milestone 1" on March 18, 2026. The company will pay $0.50 per CVR and plans to deposit the funds with the Rights Agent by early June 2026. Despite a recent GAAP net loss in Q1 2026, the company's Q1 revenue surpassed forecasts, and its share price appears undervalued according to InvestingPro analysis, with more cash than debt on its balance sheet.
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone.
Supernus Pharmaceuticals Inc. will pay Equiniti Trust Company $0.50 per share, totaling approximately $33.4 million, after reaching its first milestone under a contingent value rights agreement. This payment reflects the company's successful achievement of contractually stipulated phase results, common in drug development and M&A transactions. Equiniti Trust Company will manage and distribute these funds to eligible CVR holders.
Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call Highlights - News and Statistics
Supernus Pharmaceuticals reported strong Q1 2026 results, exceeding revenue and adjusted EBITDA estimates, driven by robust demand for key products like Onepco, Zirzuve, and Kelli. Despite an EPS miss, the company reaffirmed its full-year revenue guidance. The earnings call provided deeper insights into product performance, market penetration strategies, and future M&A considerations.
Trading Systems Reacting to (SUPN) Volatility
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) volatility using AI-generated trading systems. It highlights a neutral sentiment in the near and mid-term but a positive long-term bias, noting that support is being tested. The analysis provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with defined entry points, targets, and stop losses, and identifies an exceptional 43.0:1 risk-reward setup.
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed?
Supernus Pharmaceuticals reported stronger-than-expected Q1 2026 results with increased revenue and a narrower net loss, leading to an 8.9% stock price increase. The company reaffirmed its full-year 2026 outlook, projecting total revenues of US$840 million–US$870 million and operating earnings of US$0–US$30 million, indicating management's confidence. While the improved revenue and reaffirmed guidance support the investment narrative, the company's path to consistent profitability still depends on successful execution with its key CNS products to offset rising SG&A and R&D.
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed?
Supernus Pharmaceuticals (SUPN) reported stronger-than-expected Q1 2026 results, with revenue of US$207.71 million and a narrowing net loss. The company reaffirmed its full-year 2026 outlook, projecting revenues of US$840 million–US$870 million and operating earnings of US$0–US$30 million. This performance and guidance reinforce the investment narrative that Supernus's CNS focus and product pipeline can drive consistent profitability, though profitability challenges remain a near-term risk.
Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative
Supernus Pharmaceuticals (SUPN) reported Q1 2026 revenue of US$207.7 million and a basic EPS loss of US$0.04, improving from a US$0.21 loss in Q1 2025. Despite narrowing losses, the company still faces persistent loss-making margins and earnings volatility, with trailing twelve-month revenue at US$776.8 million and a net loss of US$29.0 million. The article discusses both bullish sentiments, citing a lower Price/Sales ratio compared to peers and fair value, and bearish concerns regarding the inconsistent profitability and product concentration risks.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals, Inc. announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026. The biopharmaceutical company, which focuses on CNS diseases, will make a live audio webcast of the presentation available for investors. An archived replay will also be accessible on the company's website for 60 days.
Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative
Supernus Pharmaceuticals reported a Q1 2026 loss of US$0.04 EPS on US$207.7 million in revenue, a narrowing from previous losses, and trailing 12-month revenue of US$776.8 million with a net loss of US$29.0 million. The company's valuation metrics, including a P/S ratio of 3.8x compared to an industry average of 5.5x, suggest it might be undervalued based on its DCF fair value, but ongoing losses and volatile earnings swings raise concerns for investors and analysts are watching for increased profitability with new product launches.
Supernus Pharmaceuticals Reports Strong Q1 2026 Results with 56% Revenue Growth
Supernus Pharmaceuticals reported strong Q1 2026 results with a 56% increase in combined revenues from growth products and an 11% rise in adjusted operating earnings year-over-year. The company saw significant sales from Onepco, with prescriptions surpassing pre-supply constraint levels, and made progress with a second supplier for Onapro, expecting FDA submission in Q3 2026. Zirzuve also contributed substantially with $27.6 million in collaboration revenues.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026. The biopharmaceutical company focuses on developing and commercializing products for CNS diseases. A live audio webcast of the presentation will be available for investors.
Supernus offers May 12 webcast as CEO joins Bank of America event
Supernus Pharmaceuticals announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026. A live audio webcast and a 60-day archived replay will be available on the company's investor relations page. This engagement continues Supernus's pattern of active communication with the investment community, following recent positive reactions to operational updates and strong financial results.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals, Inc. announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026. The biopharmaceutical company, focused on CNS diseases, invites investors to arrange meetings with management and provides access to a live audio webcast of the presentation. An archived replay will be available for 60 days on their website.
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance
Supernus Pharmaceuticals (SUPN) reported strong Q1 2026 results, exceeding revenue and earnings expectations, primarily driven by its key CNS products. Despite recent share price stability, the company has seen significant long-term growth with a 59.0% 1-year total shareholder return, suggesting the market might still offer opportunities as the stock is undervalued according to narrative fair value. The company's valuation hinges on the continued performance of its CNS portfolio, Qelbree and GOCOVRI, and the successful progress of its R&D pipeline.
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3
Supernus Pharmaceuticals outlined a projected revenue outlook of $840 million to $870 million for 2026. This forecast anticipates growth driven by their portfolio, including the Supernus Branded Products and SPN-830. The company also announced plans to file with the FDA in Q3 for a second supplier of ONAPGO, aiming to diversify their supply chain.
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript
Supernus Pharmaceuticals reported a strong financial position in Q1 2026, with approximately $384 million in cash and no debt, and reiterated its 2026 financial guidance for total revenues between $840 million and $870 million. The company is actively addressing supply constraints for its product Anapco and is optimistic about the growth of Zerzuve and Calbri, while exploring strategic acquisitions. Supernus is also working to bring a second Anapco supplier online by mid-2027 to ensure supply continuity.
Supernus (NASDAQ: SUPN) posts 39% revenue growth and reaffirms 2026 outlook
Supernus Pharmaceuticals (NASDAQ: SUPN) reported a strong Q1 2026 with total revenues increasing by 39% year-over-year to $207.7 million, driven by its CNS product portfolio including Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE. The company narrowed its GAAP net loss to $2.3 million and increased non-GAAP adjusted operating earnings to $28.7 million. Supernus also reaffirmed its full-year 2026 guidance, projecting total revenues between $840 million and $870 million.
Supernus: Q1 Earnings Snapshot
Supernus Pharmaceuticals Inc. reported a Q1 loss of $2.3 million, or 4 cents per share. After adjustments for amortization and stock options, earnings were 59 cents per share. The company generated $207.7 million in revenue for the first quarter.
[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report
Supernus Pharmaceuticals, Inc. (SUPN) filed its Quarterly Earnings Report (10-Q) for the period ended March 31, 2026. The company reported total revenues of $207.7 million, an increase from $149.8 million in the same period last year, primarily driven by strong net product sales from Qelbree and GOCOVRI, and the addition of ONAPGO and ZURZUVAE. Net loss decreased to $2.3 million from $11.8 million in Q1 2025.
Supernus Announces First Quarter 2026 Financial Results
Supernus Pharmaceuticals announced strong first-quarter 2026 financial results, with total revenues increasing 39% year-over-year to $207.7 million. This growth was primarily driven by a 56% increase in combined revenues from their four growth products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company reiterated its full-year 2026 financial guidance, anticipating continued strong performance across its key products and pipeline developments.
Supernus faces earnings test as Onapgo launch gains traction
Supernus Pharmaceuticals Inc. is set to report its first-quarter earnings, with investors keenly watching for a return to profitability and the sales trajectory of its new Parkinson's drug, Onapgo. After facing initial supply constraints, Onapgo's launch traction and the performance of other growth drivers like Qelbree, GOCOVRI, and Zurzuvae will be critical in assessing the company's financial health and future outlook. Analysts anticipate improved earnings per share but a slight revenue decline sequentially, maintaining a strong buy rating on the stock.
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 5.0% in Q4 2025, selling 25,526 shares but retaining 483,399 shares valued at $24.76 million. Insider selling has also increased, with company insiders selling 120,881 shares worth approximately $6.14 million over the last 90 days. Despite this, analysts hold a consensus "Hold" rating for SUPN with a price target of $62.17.
Vanguard (NASDAQ: SUPN) owns 2.9M Supernus shares, 5.03% stake
Vanguard Capital Management has disclosed a passive beneficial ownership of 2,900,884 shares of Supernus Pharmaceuticals Inc (SUPN), representing a 5.03% stake. The SEC filing, a Schedule 13G, indicates Vanguard holds sole voting power over 433,669 shares and sole dispositive power over all 2,900,884 shares. This disclosure provides transparency on significant ownership in Supernus, highlighting Vanguard's investment position without aiming for control.
Vanguard Portfolio Management (NASDAQ: SUPN) holds 3.26M shares, 5.66%
Vanguard Portfolio Management has reported beneficial ownership of 3,263,309 shares of Supernus Pharmaceuticals (NASDAQ: SUPN), representing 5.66% of the class as of March 31, 2026. The Schedule 13G filing indicates that Vanguard holds sole dispositive power over all these shares, but sole voting power over only 24,616 shares. The filing was signed by Ashley Grim on April 29, 2026.
Pharmaceutical Company Sued For Antitrust Appeals No D&O Coverage Ruling
A pharmaceutical company is appealing a Maryland federal court's decision to dismiss its lawsuit against a directors and officers liability insurer. The company is seeking coverage for an underlying antitrust action related to its acquisition of rights to distribute a prescription medication for Parkinson's disease. The appeal challenges the earlier ruling that denied coverage.
BofA cuts Supernus Pharmaceuticals stock price target on costs
BofA Securities has lowered its price target for Supernus Pharmaceuticals (NASDAQ:SUPN) from $65 to $62, while maintaining a Buy rating. This adjustment is attributed to increased operating expenses from product launches and refined sales projections for Onapgo, alongside an increased discount rate. Despite the reduced price target, Supernus Pharmaceuticals has shown strong performance, analysts expect profitability this year, and key product sales are aligning with expectations.
BofA cuts Supernus Pharmaceuticals stock price target on costs By Investing.com
BofA Securities has lowered its price target for Supernus Pharmaceuticals (NASDAQ:SUPN) to $62 from $65, while maintaining a Buy rating. The adjustment reflects increased operating expenses due to product launches and a revised sales projection for Onapgo, alongside a raised discount rate. Despite the reduced price target, the firm still sees Onapgo having a peak sales potential of $350 million, and InvestingPro analysis suggests Supernus is currently undervalued.
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
This article analyzes the Q4 results for several branded pharmaceutical companies, with a focus on Supernus Pharmaceuticals (SUPN). It highlights Supernus's strong revenue beat and strategic progress in 2025, despite a subsequent stock dip. The article also provides a comparative analysis of Eli Lilly (LLY) as the best performer and Corcept (CORT) as the weakest in Q4, along with results for Merck (MRK) and Pfizer (PFE).
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Recent Shareholder Returns
Supernus Pharmaceuticals (SUPN) has seen significant investor attention due to its strong recent performance, with 1-year shareholder returns of over 60%. The company, which focuses on central nervous system conditions, is currently considered undervalued by a key model, with a narrative fair value of $63.17 against a last close of $50.39. This undervaluation is attributed to the expanding patient base for its core products and strategic market positioning, despite a net loss of US$38.55m.
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Recent Shareholder Returns
Supernus Pharmaceuticals (SUPN) has shown strong shareholder returns over the past year and is currently considered 20.2% undervalued by one analytical model, trading at $50.39 against a fair value of $63.17. The company's revenue growth of 12.69% and a net loss of US$38.55m, coupled with expanding patient pools for its core products Qelbree and GOCOVRI, suggest potential for future upside. However, investors are advised to review the associated risks and the detailed growth narrative to determine if the valuation gap can be justified.
(SUPN) and the Role of Price-Sensitive Allocations
This article provides an analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), indicating neutral near and mid-term readings but a positive long-term bias. It highlights an exceptional 40.7:1 risk-reward setup, targeting an 11.5% gain versus 0.3% risk. The article details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals will announce its first-quarter 2026 financial and business results after market close on Tuesday, May 5, 2026. President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call and webcast to discuss these results at 4:30 p.m. ET on the same day. A live webcast and replay will be available on the company's Investor Relations website.
Supernus (SUPN) sets May 5 call to discuss Q1 2026 results
Supernus Pharmaceuticals, Inc. announced it will release its first-quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results, with a replay available for 60 days on their Investor Relations website. Supernus specializes in developing and commercializing treatments for central nervous system diseases.
Supernus will detail first-quarter results after markets close May 5
Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report its first-quarter 2026 financial and business results after market close on Tuesday, May 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET, with management presenting prepared remarks followed by a Q&A session. A replay of the webcast will be available on the company's Investor Relations website for 60 days.
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced it will report its first quarter 2026 financial and business results after market close on Tuesday, May 5, 2026. Following this, President and CEO Jack Khattar and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET to discuss the results and take questions. A replay of the webcast will be available on the company's Investor Relations website.
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals, Inc. announced it will release its first-quarter 2026 financial results after the market closes on Tuesday, May 5, 2026. Following the release, President and CEO Jack Khattar and SVP and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET to discuss the results and answer questions. A replay of the webcast will be available on the company's Investor Relations website.
Latest SUPN News - Supernus Announces First Quarter 2020 Finan...
Supernus Pharmaceuticals announced its first-quarter 2020 financial results, reporting a total revenue of $95.0 million, an 11% increase year-over-year. Net product sales also grew by 11% to $92.5 million, with operating earnings increasing by 14% to $29.0 million. The company is preparing for the launch of SPN-812 pending FDA approval and anticipates closing the acquisition of the CNS portfolio from US WorldMeds in Q2 2020.
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820
The article reports that Supernus Pharmaceuticals has completed its previously announced asset acquisition of SPN-820 (formerly VT-105) from Navitor Pharmaceuticals. The deal involved an upfront payment of $100 million and includes potential milestone payments up to $250 million. Supernus plans to advance SPN-820, a novel mTORC1 activator, into Phase 2 development for the treatment of depression.
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals
Tudor Investment Corp ET AL has invested $1.43 million in Supernus Pharmaceuticals, purchasing 30,015 shares. This investment by the hedge fund signals confidence in the specialty pharmaceutical company's growth potential and its focus on developing CNS therapies. The transaction was disclosed on April 13, 2026, and highlights continued institutional interest in Supernus Pharmaceuticals' product pipeline and financial outlook.
Responsive Playbooks and the SUPN Inflection
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) shows strong sentiment across all horizons, leading to an overweight bias according to AI models. The analysis highlights a mid-channel oscillation pattern with an exceptional 40.0:1 risk-reward setup, targeting an 11.3% gain with a minimal 0.3% risk. Three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis indicating strong signals across near-term, mid-term, and long-term horizons.
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong 1 Year Returns And Pipeline Progress
Supernus Pharmaceuticals (SUPN) has shown strong 1-year returns of 62.5% despite recent mixed short-term performance. The company is considered 18.3% undervalued with a narrative fair value of approximately $63.17, driven by deep pipeline progress in late-stage candidates like SPN-820 and SPN-443. However, risks include heavy reliance on key existing products and execution challenges with new offerings.
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong 1 Year Returns And Pipeline Progress
Supernus Pharmaceuticals (SUPN) has shown strong 1-year returns of 62.5% despite recent mixed short-term performance. The stock is considered 18.3% undervalued, with a narrative fair value of approximately $63.17, driven by deep pipeline progress in late-stage candidates like SPN-820 and SPN-443. Investors are advised to examine underlying data and consider potential risks such as reliance on key products.
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820).
Supernus Pharmaceuticals has agreed to acquire the asset portfolio for the candidate drug NV-5138 (SPN-820), as disclosed in a recent SEC filing. This acquisition includes both the core intellectual property rights and existing inventory of the drug. The move is a strategic step for Supernus to expand its product pipeline.
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event
Supernus Pharmaceuticals, Inc. has acquired all rights to the compound NV-5138 (SPN-820) from Navitor Pharmaceuticals, Inc., through an asset purchase agreement. The acquisition involves Supernus completing one Phase 2b study and potentially paying up to $350 million in milestone payments based on development, regulatory, and commercial achievements. A key clause allows Supernus to cease further obligations if the Phase 2b study is unsuccessful, limiting its downside risk.
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820).
Supernus Pharmaceuticals has agreed to acquire the asset portfolio for the candidate drug NV-5138 (SPN-820), as disclosed in an SEC filing. This acquisition includes the drug's core intellectual property rights and existing inventory. The move is a strategic step for Supernus Pharmaceuticals to expand its product pipeline.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
This article analyzes Supernus Pharmaceuticals, Inc.'s recent stock performance as it reached a new 52-week high. It will likely discuss factors contributing to this surge and whether the stock has further potential for growth. Investors would be interested in the analysis of its valuation and market position.
Understanding the Setup: (SUPN) and Scalable Risk
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), identifying a strong near-term sentiment with a long-term positive bias, following a mid-channel oscillation pattern. It highlights an exceptional 39.6:1 risk-reward setup targeting an 11.2% gain versus 0.3% risk. The article outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles using AI-generated signals and risk management parameters.
Hennion & Walsh Asset Management Inc. Has $4.01 Million Position in Supernus Pharmaceuticals, Inc. $SUPN
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 20.7% in Q4, holding 80,651 shares valued at $4.01 million. This comes as company insiders have sold a substantial amount of stock, with CEO Jack A. Khattar selling shares worth $1.76 million in March. Analysts currently have a mixed view on SUPN, with a consensus "Hold" rating and an average target price of $62.17 against its current trading price of around $49.35.
Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN
Tudor Investment Corp ET AL has made a new investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), purchasing 30,015 shares valued at approximately $1.43 million, representing 0.05% of the company. Despite this new institutional interest, insiders have been net sellers, with the CEO and other insiders selling a significant number of shares. Analyst sentiment towards SUPN is mixed, with an average "Hold" rating and an average price target of $62.17.
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 45.6% in the third quarter, while several other institutional investors increased their positions. Notably, insiders, including the company's director and CEO, have sold a substantial amount of shares recently. Analysts currently have a mixed outlook on SUPN, with a consensus "Hold" rating and a price target of $62.17.
